+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 693 Pages
  • August 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5146930
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Pipeline Review, H2 2020, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews the key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 36, 26, 2, 69, 24 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Table of Contents

Introduction
  • Crohn's Disease (Regional Enteritis) - Overview
  • Crohn's Disease (Regional Enteritis) - Therapeutics Development

Crohn's Disease (Regional Enteritis) - Therapeutics AssessmentCrohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics DevelopmentCrohn's Disease (Regional Enteritis) - Drug Profiles
Crohn's Disease (Regional Enteritis) - Dormant Projects
  • Crohn's Disease (Regional Enteritis) - Discontinued Products
  • Crohn's Disease (Regional Enteritis) - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H2 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by 9 Meters Biopharma Inc, H2 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H2 2020
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2020
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4D Pharma Plc
  • 9 Meters Biopharma Inc
  • AbbVie Inc
  • Abivax SA
  • Aclaris Therapeutics Inc
  • Active Biotech AB
  • Affilogic SAS
  • Aibios Co Ltd
  • Alfasigma SpA
  • Algernon Pharmaceuticals Inc
  • Allergan Ltd
  • Alpha Cancer Technologies Inc
  • Alvotech ehf
  • Amgen Inc
  • Anterogen Co Ltd
  • Arena Pharmaceuticals Inc
  • Artelo Biosciences Inc
  • Artizan Biosciences Inc
  • Asdera LLC
  • Assembly Biosciences Inc
  • AstraZeneca Plc
  • Atlantic Bio Sci LLC
  • Atlantic Healthcare Plc
  • Avexegen Therapeutics Inc
  • Avobis Bio LLC
  • Axim Biotechnologies Inc
  • BioLingus AG
  • Biond Biologics Ltd
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Celltrion Inc
  • Celularity Inc
  • Cerecor Inc
  • ChemoCentryx Inc
  • Chong Kun Dang Pharmaceutical Corp
  • ChunLab Inc
  • Cloud Pharmaceuticals Inc
  • Commence Bio Inc
  • Curacle Co Ltd
  • Cytocom Inc
  • Cytodyn Inc
  • Dadang & BIO Co Ltd
  • Daiichi Sankyo Co Ltd
  • DBV Technologies SA
  • Defensin Therapeutics ApS
  • Denali Therapeutics Inc
  • DM Bio Ltd
  • DNX Biopharmaceuticals Inc
  • EA Pharma Co Ltd
  • Educell doo
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Enterome Bioscience SA
  • Enzo Biochem Inc
  • ExCellThera Inc
  • Exeliom Biosciences SAS
  • Ferring International Center SA
  • Finch Therapeutics Group
  • FYB202 GmbH & Co KG
  • Galactica Biotech Ltd
  • Galapagos NV
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Gossamer Bio Inc
  • HAV Vaccines Ltd
  • Iltoo Pharma
  • Immunic Inc
  • Inception Sciences Inc
  • InflammatoRx inc
  • Innovation Pharmaceuticals Inc
  • Innovative Pharmacological Research (IPHAR) Co Ltd
  • Innovent Biologics Inc
  • Innovimmune Biotherapeutics Inc
  • InSight Biopharmaceuticals Ltd
  • Inspyr Therapeutics Inc
  • Intract Pharma Ltd
  • JHL Biotech Inc
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Jyant Technologies Inc
  • Kang Stem Biotech Co Ltd
  • Koutif Therapeutics LLC
  • Landos Biopharma Inc
  • Locus Biosciences Inc
  • Machavert Pharmaceuticals LLC
  • MAKScientific LLC
  • Menemsha Pharmaceuticals Ltd
  • Mesoblast Ltd
  • Metacrine Inc
  • MetiMedi Pharmaceuticals Co Ltd
  • MGC Pharmaceuticals Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Morphic Holding Inc
  • Mycenax Biotech Inc
  • NeuClone Pty Ltd
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nimbus Therapeutics LLC
  • Oncodesign SA
  • Orchard Therapeutics Plc
  • Origo Biopharma SL
  • PanTheryx Inc
  • Par'Immune SAS
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Pharmapraxis
  • Polpharma Biologics
  • Praeventix LLC
  • Prometheus Biosciences Inc
  • Protagonist Therapeutics Inc
  • Qu Biologics Inc
  • Re-Pharm Ltd
  • Rebiotix Inc
  • RedHill Biopharma Ltd
  • Redx Pharma Plc
  • Regentys Corp
  • Reponex Pharmaceuticals Aps
  • Saje Pharma LLC
  • Saniona AB
  • Semorex Technologies Ltd
  • Seres Therapeutics Inc
  • Siam Bioscience Co Ltd
  • SLA Pharma AG
  • Soligenix Inc
  • STERO Biotechs Ltd
  • Suzhou Connect Biopharmaceuticals Ltd
  • Synedgen Inc
  • Synlogic Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Temisis Therapeutics
  • Tetherex Pharmaceuticals Corp
  • The Cell Factory BVBA
  • Theravance Biopharma Inc
  • Thetis Pharmaceuticals LLC
  • Tiziana Life Sciences Plc
  • TRACT Therapeutics Inc
  • Trio Medicines Ltd
  • Ventria Bioscience
  • VHsquared Ltd
  • Winston Pharmaceuticals Inc
  • XBiotech Inc
  • Xbrane Biopharma AB
  • Yom Chai